Zeina Jeha, MD
Internal Medicine · Lewes, DENPI 1669473641
Payments from drug & device makers
Across 94 payments — averaging $22.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$397
- Amgen$301
- AstraZeneca$248
- Lilly USA, LLC$183
- Johnson & Johnson$143
- Abbott$140
- plus $722 from 17 others
What the payments were for
- Food & beverage$2,135100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 5 | $397 |
| Amgen | 18 | $301 |
| AstraZeneca | 17 | $248 |
| Lilly USA, LLC | 5 | $183 |
| Johnson & Johnson | 9 | $143 |
| Abbott | 2 | $140 |
| Novo Nordisk | 9 | $132 |
| Eisai Inc. | 1 | $108 |
| Novartis | 3 | $59 |
| AbbVie(2 entities) | 3 | $58 |
| Corcept Therapeutics | 4 | $53 |
| Alnylam Pharmaceuticals Inc. | 2 | $45 |
| Gilead | 2 | $44 |
| Astellas Pharma US Inc | 2 | $35 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $34 |
| Amarin Pharma, Inc. | 2 | $31 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $28 |
| E.r. Squibb & Sons, L.L.C. | 1 | $21 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $19 |
| Lundbeck LLC | 1 | $18 |
| Nuwellis, Inc. | 1 | $14 |
| Pfizer | 1 | $12 |
| Regeneron Healthcare Solutions, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PRADAXA$245
- JARDIANCE$125
- Confirm Rx$124
- KISUNLA$124
- Leqembi$108
How this compares
$2,135 in reported general payments places this provider in the 80th percentile of 477 internal medicine providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 72 | $89,207 |
| OzempicSemaglutide | 63 | $82,318 |
| EliquisApixaban | 44 | $65,075 |
| XareltoRivaroxaban | 27 | $33,057 |
| JardianceEmpagliflozin | 20 | $32,695 |
| MyrbetriqMirabegron | 22 | $23,498 |
| FarxigaDapagliflozin Propanediol | 16 | $21,619 |
| LinzessLinaclotide | 16 | $15,335 |
| NexlizetBempedoic Acid/Ezetimibe | 11 | $11,884 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 32 | $10,063 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 38 | $8,361 |
| Breo ElliptaFluticasone/Vilanterol | 19 | $7,498 |
| PremarinEstrogens, Conjugated | 12 | $7,114 |
| TradjentaLinagliptin | 12 | $6,055 |
| Dexlansoprazole DrDexlansoprazole | 12 | $5,444 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $183 | $89,20772 claims |
| Novo NordiskOzempic | $132 | $82,31863 claims |
| PfizerEliquis, Premarin, Paxlovid | $12 | $73,58583 claims |
| Boehringer IngelheimJardiance, Tradjenta | $397 | $38,75032 claims |
| Johnson & JohnsonXarelto | $143 | $33,05727 claims |
| Astellas Pharma US IncMyrbetriq | $35 | $23,49822 claims |
| AstraZenecaFarxiga | $248 | $21,61916 claims |
| AbbVieLinzess, Synthroid | $58 | $19,82475 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 477 internal medicine providers in Delaware.
Other internal medicine in Lewes
- Bhaskar PalekarLewes$22K
- Irene ViolaLewes$15K
- Malick IslamLewes$11K
- Charles StanislavLewes$5K
- Jennifer HurdLewes$4K
- Preachess VellahLewes$3K
- Monique YostLewes$3K
- Seth IvinsNewark$384K
- Beshara HelouGeorgetown$143K
- Tabassum SalamNewark$62K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.